ICIs Improve pCR Rates in Early ER+/HER2 – Breast Cancer ICIs Improve pCR Rates in Early ER+/HER2 – Breast Cancer

Two randomized trials highlighted the benefit of adding immune checkpoint inhibitors to neoadjuvant chemotherapy in patients with early high-risk estrogen receptor –positive, HER2-negative breast cancer.MDedge News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news